Prof. Takuya Watanabe
Tokyo University of Pharmacy and Life Sciences, Japan



1997 Ph.D., Medicine, Showa University Graduate School of Medical Sciences, Japan

1991  M.D., Medicine, Showa University School of Medicine, Japan

Publications (Selected)

  1. Watanabe T, Arita S, Shiraishi Y, Suguro T, Sakai T, Hongo S, Miyazaki A. Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. Curr Med Chem 2009;16:550-563.
  2. Watanabe T, Kanome T, Miyazaki A. Relationship between hypertension and atherosclerosis: from a viewpoint of the most potent vasoconstrictor human urotensin II. Curr Hypertens Rev 2006;2:237-246.
  3. Watanabe T, Kanome T, Miyazaki A, Katagiri T. Human urotensin II linking hypertension and coronary artery disease. Hypertens Res 2006;29:375-387.
  4. Watanabe T, Kanome T, Suguro T, Miyazaki A. Human urotensin II and metabolic syndrome. Vasc Dis Prev 2006;3:91-98.
  5. Miyazaki A, Kanome T, Watanabe T. Inhibitors of acyl-coenzyme A:cholesterol acyltransferase. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:463-469.
  6. Watanabe T, Miyazaki A. Roles of vasoactive agents in macrophage foam cell formation and atherosclerosis. In Miyazaki A, Imawari M (eds): Lifestyle-related diseases. Springer 2007, p.89-96.
  7. Hongo S, Watanabe T, Takahashi K, Miyazaki A. Acceleration of foam cell formation by leptin in human monocyte-derived macrophages. In Miyazaki A, Imawari M (eds): Lifestyle-related diseases. Springer 2007, p. 155-158.
  8. Miyazaki A, Watanabe T. Acyl-coenzyme A: cholesterol acyltransferase (ACAT). Nippon Rinsho 2004;62 Suppl 12:89-91.
  9. Watanabe T, Akutsu Y, Katagiri T, Michihata T, Okazaki O, Harumi K. Assessment of myocardial viability with electrocardiographic ST-segment changes induced by low-level exercise. Electrocardiology '97, 1998, p. 311-315.
  10. Yoshinaka Y, Shibata H, Kobayashi H, Kuriyama H, Shibuya K, Tanabe S, Watanabe T, Miyazaki A. A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice. Atherosclerosis 2010;213:85-91.
  11. Hirano T, Nohtomi K, Nakanishi N, Watanabe T, Hyodo T, Taira T. Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients. Clin Nephrol 2010;74:282-287.
  12. Yamagata B, Watanabe T, Tomioka H, Kobayashi H, Nakano Y, Mimura M.Preliminary use of insulin-like growth factor-I as a biomarker for sorting out high-dose donepezil responders in Japanese patients with Alzheimer’s disease. Regul Peptides 2010;163:137-142.
  13. Kimoto S, Sato K, Watanabe T, Suguro T, Koyama T, Shichiri M. Serum levels and urinary excretion of salusin-a in renal insufficiency. Regul Peptides 2010;162:129-132.
  14. Nagashima M, Watanabe T, Shichiri M, Sato K, Shiraishi Y, Morita R, Terasaki M,Arita S, Hongo S, Miyazaki A, Hirano T.Chronic infusion of salusin-a and -b exerts opposite effects on macrophage foam cell formation and atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2010;212:70-77.
  15. Xu G,* Watanabe T,* Iso Y, Koba S, Sakai T, Nagashima M, Arita S, Hongo S, Ota H, Kobayashi Y, Miyazaki A, Hirano T. Preventive effects of heregulin-b1 on macrophage foam cell formation and atherosclerosis. Circ Res 2009;105:500-510.
  16. Ban Y, Watanabe T, Suguro T, Miyazaki A, Matsuyama T, Iso Y, Sakai T, Ota H, Idei T, Kato N, Nakano Y, Sato R, Ban Y, Kobayashi Y. Increased plasma human urotensin II levels and carotid atherosclerosis are associated with vascular dementia. J Atheroscler Thromb 2009;16:179-187.
  17. Hongo S, WatanabeT, Kanome T, Kageyama H, Shioda S, Miyazaki A. Leptin modulates ACAT-1 expression and cholesterol efflux from human macrophages. Am J Physiol Endocrinol Metab2009;297:474-482.
  18. Kanome T, Watanabe T, Nishio K, Takahashi K, Hongo S, Miyazaki A. Angiotensin II upregulates acyl-CoA:cholesterol acyltransferase-1 via the angiotensin II type 1 receptor in human monocyte-macrophages. Hypertens Res 2008;31:1801-1810.
  19. Shiraishi Y, Watanabe T, Suguro T, Nagashima M, Kato R, Hongo S, Itabe H, Miyazaki A, Hirano T, Adachi M. Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. J Hypertens 2008;26:1955-1965.
  20. Suguro T, Watanabe T, Kodate S, Xu G, Hirano T, Adachi M, Miyazaki A. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin Sci (Lond) 2008;115:327-334.
  21. Watanabe T, Suguro T, Sato K, Koyama T, Nagashima M, Kodate S, Hirano T, Adachi M, Shichiri M, Miyazaki A. Serum salusin-a levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. Hypertens Res2008;31:463-468.
  22. Watanabe T, Nishio K, Kanome T, Matsuyama T, Koba S, Sakai T, Sato K, Hongo S, Nose K, Ota H, Kobayashi Y, Katagiri T, Shichiri M, Miyazaki A. Impact of salusin-a and -b on human macrophage foam cell formation and coronary atherosclerosis. Circulation 2008;117:638-648.
  23. Tei E, Watanabe T, Yamamoto H, Miyazaki A, Nakadate T, Kato N, Mimura M. Use of serum insulin-like growth factor-1 levels to predict psychiatric non-response to donepezil in patients with Alzheimer’s disease. Growth Horm IGF Res 2008;18:47-54.
  24. Ban Y, Watanabe T, Miyazaki A, Idei T, Iguchi T, Katagiri T. Impact of increased plasma serotonin levels and carotid atherosclerosis on vascular dementia. Atherosclerosis 2007;195:153-159.
  25. Watanabe T, Takahashi K, Kanome T, Hongo S, Koba S, Katagiri T, Miyazaki A, Pakala R, Benedict CR. Human urotensin-II potentiates mildly oxidized LDL-induced vascular smooth muscle cell proliferation: Comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res 2006;29:821-831.
  26. Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T, Miyazaki A, Adachi M. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007;20:211-217.
  27. Ikenoya M, Yoshinaka Y, Kobayashi H, Kawamine K, Shibuya K, Sato F, Sawanobori K, Watanabe T, Miyazaki A. A selective ACAT-1 inhibotor, K-604, suppress fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis 2007;191:290-297.
  28. Hongo S, Watanabe T, Takahashi K, Miyazaki A. Ndrg4 enhances NGF-induced ERK activation uncoupled with Elk-1 activation. J Cell Biochem 2006;98:185-193.
Free SCIRP Newsletters
Copyright © 2006-2023 Scientific Research Publishing Inc. All Rights Reserved.